Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Amicus Therapeutics
Amicus Therapeutics
Activities:
Research & Development
Finance
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Manufacturing
Catalent wins CDMO contract with Amicus Therapeutics
The US biotech company has chosen Paragon Gene Therapy development and manufacturing capability for lysosomal disorder programmes
Manufacturing
Amicus chooses Thermo Fisher for gene therapy CDMO services
Collaboration will focus on the rare genetic cause of Batten disease
Design & Build
Amicus builds global R&D centre for gene therapy in the US
Located in Philadelphia, the new 75,000 sqft facility will be completed in the second half of 2019
Manufacturing
WuXi Biologics inks commercial agreement with Amicus
Chinese biotech company has become exclusive drug substance manufacturing partner and key commercial drug product supplier for Pompe biologic ATB200
Research & Development
Drug licensing deals in 2010
Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Research & Development
GSK and Amicus Therapeutics sign exclusive agreement
To develop and commercialise Amigal for Fabry disease
Subscribe now